0001104659-24-042335.txt : 20240402 0001104659-24-042335.hdr.sgml : 20240402 20240402111238 ACCESSION NUMBER: 0001104659-24-042335 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240326 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Electromedical Technologies, Inc CENTRAL INDEX KEY: 0001715819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 822619815 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56192 FILM NUMBER: 24812692 BUSINESS ADDRESS: STREET 1: 16561 N 92ND STREET STREET 2: SUITE 101 CITY: SCOTTSDALE STATE: AZ ZIP: 85260 BUSINESS PHONE: 888-880-7888 MAIL ADDRESS: STREET 1: 16561 N 92ND STREET STREET 2: SUITE 101 CITY: SCOTTSDALE STATE: AZ ZIP: 85260 8-K 1 tm2410575d1_8k.htm FORM 8-K
false 0001715819 0001715819 2024-03-26 2024-03-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 26, 2024

 

 

ELECTROMEDICAL TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware Commission File Number 82-2619815
(State or other jurisdiction of
incorporation or organization)		 000-56192 (I.R.S. Employer
Identification Number)

 

16561 N. 92nd Street, Ste. 101

Scottsdale, AZ 85260

 (Address of Principal Executive Offices and Zip Code) 

 

888-880-7888

(Issuer's telephone number)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbols Name of Exchange on Which Registered
COMMON EMED NONE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Section 8 - - Other Events

 

Item 8.01 Other Events.

 

Effective March 25, 2024, the Company entered into a mutual settlement and release agreement with Mast Hill Fund, LP, concerning three security purchase agreements and associated warrant agreements dated October 13, 2021, February 11, 2022, and September 15, 2022. The mutual settlement and release agreement resolved respective defaults or cross defaults of the respective notes, the default amounts under the notes, including the payment of principal, accrued interest, default interest, and legal fees. The terms of the mutual settlement and release agreement included (i) cancellation of all outstanding warrants issued pursuant to the respective security purchase agreements and (ii) a waiver of the interest and default interest due under the respective security purchase agreements until a new and mutually agreed to maturity date of September 25, 2025. The parties agreed that interest shall accrue on the 12% per annum on the balance. The mutual settlement and release agreement also provided for repayment terms, including the Company's agreement to pay Mast Hill Fund, LP a 15% portion of money raised by the Company while the respective notes are outstanding and an agreement to pay Mast Hill Fund, LP a portion of its proceeds from sales equal to a pro-rata portion of proceeds from the Company's current and future sales on its products.

 

This 8-K filing contains a summary description of certain terms of the settlement and mutual release agreement entered into by the "Company" and Mast Hill Fund, LP. This summary is provided for informational purposes only and does not purport to be complete. The summary is qualified in its entirety by reference to the complete agreement, a copy of which is attached hereto as an exhibit.

 

Section 9 – Financial Statement and Exhibits

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No. Document Location
     
20.1 Mutual Settlement and Release Agreement Filed Herewith

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated April 2, 2024

 

ELECTROMEDICAL TECHNOLOGIES, INC.

 

By:/s/ Matthew Wolfson 
Matthew Wolfson 
Chief Executive Officer 
(Principal Executive Officer) 

 

 

 EX-20.1 2 tm2410575d1_ex20-1.htm EXHIBIT 20.1

 

Exhibit 20.1

 

SETTLEMENT AND MUTUAL RELEASE AGREEMENT

 

THIS SETTLEMENT AND MUTUAL RELEASE AGREEMENT (this “Agreement”) dated as of March 25, 2024 (the “Effective Date”), is made by and between ELECTROMEDICAL TECHNOLOGIES, INC., a Delaware corporation (the “Company”) and Mast Hill Fund, L.P., a Delaware limited liability partnership (the “Investor”) (the Company and the Investor are each also referred to herein as a “Party”, and together as the “Parties”).

 

WHEREAS, on or around October 13, 2021, the Company and the Investor entered into a securities purchase agreement (the “First SPA”), pursuant to which the Company issued to the Investor a promissory note in the principal amount of $500,000.00 (as amended from time to time, the “First Note”) and the Warrant (as defined in the First SPA) (the “First Warrant”); and

 

WHEREAS, on or around February 11, 2022, the Company and the Investor entered into a securities purchase agreement (the “Second SPA”), pursuant to which the Company issued to the Investor a promissory note in the principal amount of $307,500.00 (as amended from time to time, the “Second Note”) and the Warrants (as defined in the Second SPA) (the “Second Warrants”); and

 

WHEREAS, on or around September 15, 2022, the Company and the Investor entered into a securities purchase agreement (the “Third SPA”, and collectively with the First SPA and Second SPA, the “Purchase Agreements”), pursuant to which the Company issued to the Investor a promissory note in the principal amount of $896,000.00 (as amended from time to time, the “Third Note”, and collectively with the First Note and Second Note, the “Notes” and each a “Note”) and the Warrants (as defined in the Third SPA) (the “Third Warrants”, and collectively with the First Warrant and Second Warrants, the “Warrants”); and

 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.Settlement; Modifications to Transaction Documents.

 

a.The Purchase Agreements, Notes, Warrants, and all other ancillary documentation entered into with respect to the Purchase Agreements, Notes, and Warrants shall collectively be referred to herein as the “Transaction Documents”.

 

b.Each of the Warrants shall be cancelled without consideration.

 

c.Notwithstanding any provision of the Notes to the contrary, the Company shall have no obligation to pay any interest under the Notes (either current interest or default interest (including Default Interest (as defined in the Notes)) until the Maturity Date (as amended by this Agreement). All Default Interest that has accrued under the Notes prior to the Effective Date shall remain outstanding under the Notes, provided, however, that the interest rate (current interest and default interest) under the Notes shall be capped at 12.0% per annum beginning on the Effective Date until paid in full. The Parties acknowledge and agree that the total outstanding balances of the Notes as of the Effective Date are as follows: (i) $90,639.08 of principal and accrued interest under the First Note, (ii) $53,234.03 of principal and accrued interest under the Second Note, and (iii) $917,490.87 of principal and accrued interest under the Third Note.

 

-1-

 

 

Notwithstanding anything to the contrary in the Transaction Documents, including but not limited to Section 1.10 of the Notes, the Parties hereby agree that if, at any time prior to the full repayment or full conversion of all amounts owed under the applicable Note, the Company or any of the Company’s Subsidiaries (as defined in the Purchase Agreement) receives cash proceeds from any source or series of related or unrelated sources on or after the Effective Date, including but not limited to, from payments from customers other than with respect to the Unit Payments described in Section 1(m) of this Agreement, the issuance of equity or debt, the incurrence of indebtedness for borrowed money, a merchant cash advance, sale of receivables or similar transaction, the conversion of outstanding warrants of the Company or any of the Company’s Subsidiaries, the issuance of securities pursuant to an Equity Line of Credit (as defined in the Notes) of the Company, or the sale of assets by the Company or any of the Company’s Subsidiaries (for the avoidance of doubt, the unit sales giving rise to the Unit Payments described in Section 1(m) of this Agreement shall not give rise to payment obligations of the Company under in this Section 1(c)), the Company shall, (i) inform the Investor of such receipt within three (3) business days of Company’s or the Subsidiaries’ receipt of such proceeds and (ii) pay to the Investor under the applicable Note an amount equal to such Investor’s Pro-rata Portion (as defined in this Agreement) under the applicable Note multiplied by 15% of such proceeds for the repayment of the outstanding Principal Amount (as defined in the Notes) and interest (including any Default Interest) then due under the applicable Note within five (5) business days of Company’s or the Subsidiaries’ receipt of such proceeds; provided, that, the first $150,000 of any such proceeds received by the Company or the Company Subsidiaries shall not be subject to this repayment obligation under any of this Note or the other Notes. The Parties hereby agree that the promissory note issued by the Company to 1800 Diagonal Lending LLC on or about March 11, 2024 in the principal amount of $149,500 shall be considered within the $150,000 referenced in the proviso above and that the issuance of, and performance under, such note shall not be an Event of Default under the Notes. Failure of the Company to comply with this provision shall constitute an Event of Default. For purposes of this Agreement, “Pro-rata Portion” shall mean the percentage that the Principal Amount of the applicable Note represents in relation to the aggregate Principal Amounts of all of the Notes. The foregoing provisions shall supersede any conflicting provisions in the Notes.

 

-2-

 

 

d.The Parties hereby agree that all cash payments made by the Company to the Investor under the Notes, pursuant to Section 1.10 of the Notes or otherwise, shall reduce the principal owed under the Notes first, and shall only be applied to accrued interest and penalties (if applicable) under the Notes after the principal has been repaid in full.

 

  e. Notwithstanding anything to the contrary in Section 1.6(e) of the Notes, if any Dilutive Issuance (as defined in the Notes) occurs during the period beginning on the Effective Date and continuing through the date that is twelve (12) calendar months after the Effective Date (the “Affected Period”), the Conversion Price (as defined in the Notes) under each Note shall be reduced, at the option of the Investor, to a price equal to the quotient obtained by dividing by the Sum X (as defined in this Agreement) by the Sum Y (as defined in this Agreement). “Sum X” shall mean the sum of (A) the product obtained by multiplying the Common Stock Deemed Outstanding (as defined in this Agreement) prior to such Dilutive Issuance by the Conversion Price then in effect plus (B) the aggregate consideration, if any, received by the Company upon such Dilutive Issuance. “Sum Y” shall mean the sum of (A) the Common Stock Deemed Outstanding immediately prior to such Dilutive Issuance plus (B) the aggregate number of shares of Common Stock (as defined in the Notes) issued or sold (or deemed issued or sold) by the Company in such Dilutive Issuance.

 

The foregoing provisions for determining the Conversion Price in a Dilutive Issuance during the Affected Period shall supersede in their entirety the provisions in Section 1.6(e) of the Notes for determining the Conversion Price in a Dilutive Issuance. In addition, notwithstanding anything to the contrary in Section 1.6(e) of the Notes, any issuance of Common Stock or other securities convertible into, exercisable for, or which otherwise provides any person or entity the right to acquire, shares of Common Stock which contains contingencies or triggering events or circumstances to such issuance, conversion or exercise, shall only be considered a Dilutive Issuance upon the occurrence of such contingency or triggering event or circumstance. All other provisions of Section 1.6(e) of the Notes shall remain unchanged.

 

i.For the avoidance of doubt, if the Company’s issuance of Common Stock Equivalents (as defined in the Notes) resulted in the respective Dilutive Issuance, then the aggregate number of shares of Common Stock issued or sold (or deemed issued or sold) by the Company in such Dilutive Issuance shall include all shares of Common Stock underlying the respective Common Stock Equivalents (ignoring any beneficial ownership limitations applicable to such Common Stock Equivalents) that resulted in the respective Dilutive Issuance.

 

ii.“Common Stock Deemed Outstanding” shall mean (A) the number of shares of Common Stock actually outstanding (not including shares of Common Stock held in the treasury of the Company), plus (B) the maximum total number of shares of Common Stock issuable pursuant to all Common Stock Equivalents (as defined in the Notes) of the Company (ignoring any beneficial ownership limitations applicable to such Common Stock Equivalents). The Company shall provide the Common Stock Deemed Outstanding within two (2) business days of the Investor’s request.

 

-3-

 

 

iii.Notwithstanding anything to the contrary in this Agreement, Section 1(e) of this Agreement shall not apply to any Dilutive Issuance that occurred prior to the date of this Agreement, any Dilutive Issuances that occur after the Affected Period, or any Dilutive Issuances during the Affected Period that occur after the Company has received $2,000,000 (the “Maximum Threshold”) of consideration in the aggregate from the issuance of any securities during the Affected Period (for the avoidance of doubt, each time that the Company receives consideration during the Affected Period from the issuance of any securities, such amount shall be aggregated together for purposes of calculating the Maximum Threshold).

 

iv.The Company represents and warrants that, as of the Effective Date, the Conversion Price under the Notes is equal to $0.00102 per share.

 

f.If the Company fails to comply with Section 1(c) of this Agreement at any time on or after the Effective Date, then, except as set forth in the proviso below, Section 1(e) of this Agreement shall no longer apply to the Notes, and the original Section 1.6(e) of the Notes shall automatically be in full force and effect. For the avoidance of doubt, the original Section 1.6(e) of the Notes shall then apply to every Dilutive Issuance that has occurred on or after the Issue Date (as defined in the Notes) of the respective Notes (including but not limited to during the Affected Period).

 

g.Section 4(c) of the Purchase Agreements, titled “Use of Proceeds”, shall be replaced with “[Intentionally Omitted]”.

 

h.Section 4(d) of the Purchase Agreements, titled “Right of Participation and First Refusal”, shall be deleted from the Purchase Agreements.

 

i.Section 4(p) or, as applicable, Section 4(o), of the Purchase Agreements, titled “Most Favored Nation”, shall be deleted from the Purchase Agreements.

 

j.Section 4(q) or, as applicable, Section 4(p) of the Purchase Agreements, titled “Subsequent Variable Rate Transactions”, shall be deleted from the Purchase Agreements.

 

k.Notwithstanding any provisions of Section 5 of the Purchase Agreements to the contrary, the Company obligations with respect to transfer agent instructions and related matters set forth therein shall take into account the $30,000.00 monthly limit on the Investor’s conversions set forth in Section 1(n) of this Agreement.

 

-4-

 

 

l.The Maturity Date (as defined in the Notes) of the Notes shall be extended to September 25, 2025.

 

m.In addition to all other payment obligations in the Notes, the Company shall pay to each Holder under each Note applied to repayment of the outstanding Principal Amount of such Note an amount equal to such Holder’s Pro-rata Portion of $600.00 of the proceeds from the Company’s, sale of each Wellness Pro Plus Infinity unit (and any future new, modified, or upgraded versions of this unit) (collectively, the “Unit Payments”), which Unit Payments shall be made in monthly installments within five (5) business days of the end of each month (with respect to all sales of Wellness Pro Plus Infinity units (and any future new, modified, or upgraded versions of this unit) in the respective calendar month) and the Company shall provide an accounting to the Investor.

 

n.Notwithstanding the provisions of Section 1.1 of the Notes, the Investor shall only be permitted to effectuate conversions for up to $30,000.00 (of principal only, not interest) under the Notes in the aggregate per calendar month unless (i) the Company waives this limitation in writing to the Investor, (ii) the Common Stock is listed for trading on a national securities exchange (included but not limited to The Nasdaq Stock Market or NYSE), or (iii) the date of the respective conversion is after December 31, 2024.

 

o.Notwithstanding the provisions of Section 1.2(a) of the Notes, the Investor shall no longer be entitled to deduct $1,750.00 from the conversion amount in a Notice of Conversion to cover Holder’s fees with respect to any conversion under the Notes effectuated on or after the Effective Date.

 

p.Section 2.1 and 2.4 of the Notes shall be revised to except therefrom other currently outstanding promissory notes of the Company.

 

q.Section 2.6 of the Notes shall be revised to provide that the amendments and modifications to the Transaction Documents contemplated by this Agreement and the similar amendments to existing Company promissory notes and related transaction documents shall be excepted therefrom.

 

r.In Section 2.8 of the Notes, clause (c) (regarding Variable Rate Transactions(as defined in the Notes)) shall be deleted therefrom.

 

s.Section 3.14 of the Notes, titled “Cross-Default”, shall be deleted from the Notes.

 

t.Section 3.15 of the Notes, titled “Variable Rate Transactions”, shall be deleted from the Notes.

 

u.Section 3.17 of the Notes, titled “Unavailability of Rule 144”, shall be deleted from the Notes.

 

-5-

 

 

v.In Section 3.20 of the Notes, the reference to “125%” shall be replaced with “115% (meaning, for the avoidance of doubt, 1.15)”.

 

w.Section 4.14 of the Notes, titled “Terms of Future Financings”, shall be deleted from the Notes.

 

x.Section 4.16 of the Notes, titled “Right of First Refusal”, shall be deleted from the Notes.

 

y.Except as expressly set forth in this Agreement, the Purchase Agreements and the Notes shall remain unmodified and in full force and effect.

 

2.Mutual Release.

 

a.Except as expressly set forth in this Agreement, for and in consideration of the mutual covenants set forth herein, the Investor on its own behalf, and on behalf of its affiliates, partners, grantees, agents, representatives, assigns, assignors, and any person and/or entity claiming through the Investor (collectively, the “Investor Releasing Parties”), hereby irrevocably, unconditionally, and forever releases the Company and its past, present and future officers, directors, members, managers, partners, agents, consultants, employees, representatives, attorneys, accountants, consultants, advisors, partners, partnerships, parent companies, divisions, subsidiaries, owners, joint ventures, commonly-controlled companies, investors, and insurers, as applicable, together with all successors and assigns of any of the foregoing (collectively, the “Company Released Parties”), of and from all liabilities, causes of action, charges, complaints, suits, claims, obligations, costs, losses, damages, rights, judgments, attorneys’ fees, expenses, bonds, bills, penalties, fines, and all other legal responsibilities of any form whatsoever, whether known or unknown, whether previously or presently existing or arising in the future, whether suspected or unsuspected, whether fixed or contingent, including those arising under any theory of law, whether common, constitutional, statutory or other of any jurisdiction, foreign or domestic, whether in law or in equity, which they have or may claim to have against any of the Company Released Parties prior to and as of the Effective Date, including, without limitation, any costs, attorneys’ fees or expenses incurred by the Investor Releasing Parties prior to and as of the Effective Date, solely under and in relation to the Transaction Documents and the transactions contemplated thereby, which, for the avoidance of doubt, shall not release the Company from its continuing obligations under the Purchase Agreements or the Notes (as modified by this Agreement); provided, that, this release shall not extend to (i) any obligations incurred under, or arising out of, this Agreement or (ii) any claims or causes of action against the Mailander Law Office, Inc. or Tad Mailander in connection with or relating to any legal opinions issued by the Mailander Law Office, Inc. or Tad Mailander to Investor, including but not limited to the opinion issued to Investor on or around September 28, 2022 (which, for the avoidance of doubt shall not modify the release of the Company Released Parties (other than the Mailander Law Office, Inc. and Tad Mailander with respect to the matters described in clause (ii) of this proviso) (all of the aforementioned are collectively referred to as the “Investor Released Claims”). The Investor Releasing Parties hereby acknowledge and agree that, except as expressly set forth in this Agreement and the Transaction Documents (as modified by this Agreement), the Company Released Parties have no other liabilities or obligations, of any kind or nature, owed to the Investor Releasing Parties, in connection with or relating to the Investor Released Claims or otherwise.

 

-6-

 

 

b.Except as expressly set forth in this Agreement, for and in consideration of the mutual covenants set forth herein, the Company on its own behalf, and on behalf of its affiliates, grantees, agents, representatives, assigns, assignors, and any person and/or entity claiming through the Investor (collectively, the “Company Releasing Parties”), hereby irrevocably, unconditionally, and forever releases the Investor and its past, present and future officers, directors, members, managers, partners, agents, consultants, employees, representatives, attorneys, accountants, consultants, advisors, partners, partnerships, parent companies, divisions, subsidiaries, owners, joint ventures, commonly-controlled companies, investors, and insurers, as applicable, together with all successors and assigns of any of the foregoing (collectively, the “Investor Released Parties”), of and from all liabilities, causes of action, charges, complaints, suits, claims, obligations, costs, losses, damages, rights, judgments, attorneys’ fees, expenses, bonds, bills, penalties, fines, and all other legal responsibilities of any form whatsoever, whether known or unknown, whether previously or presently existing or arising in the future, whether suspected or unsuspected, whether fixed or contingent, including those arising under any theory of law, whether common, constitutional, statutory or other of any jurisdiction, foreign or domestic, whether in law or in equity, which they have or may claim to have against any of the Investor Released Parties prior to and as of the Effective Date, including, without limitation, any costs, attorneys’ fees or expenses incurred by the Company Releasing Parties prior to and as of the Effective Date, solely under and in relation to the Transaction Documents and the transactions contemplated thereby, which, for the avoidance of doubt, shall not release the Investor from its continuing obligations under the Purchase Agreements or the Notes (as modified by this Agreement); provided, that, this release shall not extend to any obligations incurred under, or arising out of, this Agreement, provided, further, that this release shall encompass all actions of the Investor Released Parties taken prior to the Effective Date, as of the Effective Date, and at all times after the Effective Date with respect to any claim against any of the Investor Released Parties relating to registration as a broker-dealer under any state or federal laws or statutes (all of the aforementioned are collectively referred to as the “Company Released Claims”). The Company Releasing Parties hereby acknowledge and agree that, except as expressly set forth in this Agreement and the Transaction Documents (as modified by this Agreement), the Investor Released Parties have no other liabilities or obligations, of any kind or nature, owed to the Company Releasing Parties, in connection with or relating to the Company Released Claims or otherwise.

 

-7-

 

 

c.The Investor acknowledges that it may hereafter discover facts different from, or in addition to, those which he now believes to be true with respect to the claims released under this Agreement. The Investor hereby expressly and knowingly waives and relinquishes any and all rights that it has or might have under any federal or state statutes or common law principles which purport to protect a party from waiving or releasing claims of which it is not fully aware at the time of such waiver or release. The Investor agrees that the foregoing release and waiver shall be and remain effective in all respects notwithstanding such different or additional facts or discovery thereof, and that this Agreement contemplates the extinguishment of all such claims. By executing this Agreement, the Investor acknowledges the following: (a) it is represented by counsel; and (b) it has been specifically advised by counsel of the consequences of the above waiver and this Agreement generally.

 

d.The Investor further agrees, promises, and covenants that it has not and will not, nor will any person, organization or any other entity acting on its behalf, file, charge, claim, sue, participate in, join or cause or permit to be filed, charged or claimed, any action for damages or other relief (including injunctive, declaratory, monetary or other) on any claims released under this Agreement. The Investor agrees that this Agreement may be pleaded as a full and complete defense to any and all claims and causes of action being released pursuant to this Agreement. The Investor acknowledges and consents that this Agreement may be used as the basis for an injunction to halt any action, suit or other proceeding based upon claims released under this Agreement. If the Investor fails to comply with this Section 2(d), then the Company, at the Company’s sole discretion, may declare this Agreement null and void and of no further force or effect.

 

e.The Company acknowledges that it may hereafter discover facts different from, or in addition to, those which he now believes to be true with respect to the claims released under this Agreement. The Company hereby expressly and knowingly waives and relinquishes any and all rights that it has or might have under any federal or state statutes or common law principles which purport to protect a party from waiving or releasing claims of which it is not fully aware at the time of such waiver or release. The Company agrees that the foregoing release and waiver shall be and remain effective in all respects notwithstanding such different or additional facts or discovery thereof, and that this Agreement contemplates the extinguishment of all such claims. By executing this Agreement, the Company acknowledges the following: (a) it is represented by counsel; and (b) it has been specifically advised by counsel of the consequences of the above waiver and this Agreement generally.

 

-8-

 

 

f.The Company further agrees, promises, and covenants that it has not and will not, nor will any person, organization or any other entity acting on its behalf, file, charge, claim, sue, participate in, join or cause or permit to be filed, charged or claimed, any action for damages or other relief (including injunctive, declaratory, monetary or other) on any claims released under this Agreement. The Company agrees that this Agreement may be pleaded as a full and complete defense to any and all claims and causes of action being released pursuant to this Agreement. The Company acknowledges and consents that this Agreement may be used as the basis for an injunction to halt any action, suit or other proceeding based upon claims released under this Agreement. If the Company fails to comply with this Section 2(f), then the Investor, at the Investor’s sole discretion, may declare this Agreement null and void and of no further force or effect, provided, however, that Sections 2(b), 2(e), and 2(f) of this Agreement shall survive and be in full force and effect even if the Investor’s declares this Agreement as null and void.

 

g.If (i) the Company fails to comply with Section 1(c) or 1(m) of this Agreement at any time on or after the Effective Date, or (ii) an event of default occurs under Section 3.2, 3.5, 3.7, or 3.8 of any of the Notes, then the Investor, at the Investor’s sole discretion, may declare this Agreement null and void and of no further force or effect, provided, however, that Sections 2(b), 2(e), and 2(f) of this Agreement shall survive and be in full force and effect even if the Investor’s declares this Agreement as null and void.

 

3.Miscellaneous.

 

a.Notices. Any notices hereunder to the Company or the Investor shall be in writing. If sent by electronic mail, such notices shall be deemed to have been given when sent (provided that electronic confirmation of it being sent is received by the sender). If sent by hand delivery or special courier (e.g., Federal Express), such notices shall be deemed to have been given on the date of delivery thereof as reflected on written confirmation of such delivery. All notices shall be addressed as follows (or to such other address or addresses of which any party shall provide written notice to the other parties hereto).

 

If to the Company:

 

ELECTROMEDICAL TECHNOLOGIES, INC.

16561 N. 92nd Street, Ste. 101

Scottsdale, AZ 85260

Email: ceo@electromedtech.com

 

-9-

 

 

If to the Investor:

 

MAST HILL FUND, L.P.

48 Parker Road

Wellesley, MA 02482

Email: admin@masthillfund.com

 

b.Amendments. This Agreement may not be changed orally, but only by an agreement in writing signed by the Company and the Investor.

 

c.Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

 

d.Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

e.Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the Parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the Parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

f.Construction. The Parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the this Agreement or any amendments thereto.

 

-10-

 

 

g.Governing Law and Venue. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, managers, employees or agents) shall be commenced exclusively in the state or federal courts located in the Commonwealth of Massachusetts. Each party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting in the Commonwealth of Massachusetts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
   
h.Successors and Assigns. The Parties agree that this Agreement and all of its terms shall be binding on the Parties and each of them, and, as applicable, on their heirs, executors, administrators, dependents, predecessors, successors, subsidiaries, divisions, alter egos, affiliated corporations, parent corporations and related entities, and their agents, attorneys, officers, directors, successors and assigns.
   
i.No Admission. The Parties understand and acknowledge that this is a compromise, settlement and mutual release without any admission of liability or error or bad faith on the part of any party or any of its agents, prior or present attorneys, predecessors, successors, assigns, subsidiaries, divisions, alter egos, affiliated corporations and related entities, and their past or present officers, directors, partners, employees, agents and any or all of them.
   
j.Representation by Counsel. Each Party acknowledges that it has been represented by independent legal counsel of its own choice throughout all of the negotiations which preceded the execution of this Agreement and that it has executed this Agreement with the consent and on the advice of such independent legal counsel. The terms of this Agreement have been read and its consequences (including risks, complications, and costs) have been completely explained to each party by that Party's attorney. Each Party further acknowledges and represents that, in executing this Agreement, they have not relied on any inducements, promises, or representations made by the other Party hereto.

 

-11-

 

 

k.Knowing and Competent Release. Each Party acknowledges that it has read this Agreement and assents to all of the terms and conditions herein without any reservation whatsoever and it has had the same explained to it by its own counsel, who have answered all questions which have been asked of him or her with regard to the meaning of any of the provisions hereof. Each individual party to this Agreement warrants and represents that he or she is fully physically able and mentally competent to execute this Agreement and has a full and complete understanding of its terms. Furthermore, each Party affirms that no legal impediment impairs its competence to proceed with this Agreement.

 

l.Capacity and Authority to Bind. Each of the Company and the Investor represents and warrants that (i) it has all requisite corporate power and authority to enter into and perform this Agreement and to consummate the transactions contemplated hereby, (ii) the execution and delivery of this Agreement by such party and the consummation by it of the transactions contemplated hereby have been duly authorized by such party’s Board of Directors and no further consent or authorization of such party, its Board of Directors or, as applicable, its shareholders or its debt holders is required, (iii) this Agreement has been duly executed and delivered by such party by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and bind such party accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by such party, will constitute, a legal, valid and binding obligation of such party, enforceable against it in accordance with its terms.

 

m.Entire Agreement. This Agreement, together with the Transaction Documents (as modified by this Agreement), contain the entire understanding of the Company and the Investor with respect to the matters covered herein and therein and supersede all prior agreements and understandings, oral or written, with respect to such matters.

 

[SIGNATURE PAGE FOLLOWS]

 

-12-

 

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the date first above written.

 

ELECTROMEDICAL TECHNOLOGIES, INC.
   
 By:/s/ Matthew Wolfson
 Name: Matthew Wolfson
 Title: Chief Executive Officer

 

  MAST HILL FUND, L.P.
     
  By: /s/ Patrick Hassani
  Name: Patrick Hassani
  Title: Chief Investment Officer

 

-13-

 EX-101.SCH 3 elcq-20240326.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 elcq-20240326_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 elcq-20240326_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 26, 2024
Entity File Number 000-56192
Entity Registrant Name ELECTROMEDICAL TECHNOLOGIES, INC.
Entity Central Index Key 0001715819
Entity Tax Identification Number 82-2619815
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 16561 N. 92nd Street
Entity Address, Address Line Two Ste. 101
Entity Address, City or Town Scottsdale
Entity Address, State or Province AZ
Entity Address, Postal Zip Code 85260
City Area Code 888
Local Phone Number 880-7888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security COMMON
Trading Symbol EMED
Security Exchange Name NONE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://electromedtech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports elcq-20240326.xsd elcq-20240326_lab.xml elcq-20240326_pre.xml tm2410575d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2410575d1_8k.htm": { "nsprefix": "elcq", "nsuri": "http://electromedtech.com/20240326", "dts": { "schema": { "local": [ "elcq-20240326.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "elcq-20240326_lab.xml" ] }, "presentationLink": { "local": [ "elcq-20240326_pre.xml" ] }, "inline": { "local": [ "tm2410575d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://electromedtech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2410575d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2410575d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://electromedtech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-042335-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-042335-xbrl.zip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tm2410575d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001715819 2024-03-26 2024-03-26 iso4217:USD shares iso4217:USD shares false 0001715819 8-K 2024-03-26 ELECTROMEDICAL TECHNOLOGIES, INC. DE 82-2619815 000-56192 16561 N. 92nd Street Ste. 101 Scottsdale AZ 85260 888 880-7888 false false false false COMMON EMED NONE true false